Catheter Precision to Attend the 30th International Atrial Fibrillation Symposium
Catheter Precision (NYSE American:VTAK) has announced its participation in the 30th International Atrial Fibrillation Symposium, scheduled for January 16-18, 2025, in Boston, Massachusetts. The AF Symposium, established in 1995 in response to the growing atrial fibrillation epidemic, has evolved into a significant scientific forum where healthcare professionals can learn about the latest research and therapeutic advances directly from leading investigators.
CEO David Jenkins emphasized that these meetings provide valuable opportunities to showcase their technologies, generate sales leads, and facilitate educational discussions between physicians about their products, studies, and clinical techniques.
Catheter Precision (NYSE American:VTAK) ha annunciato la sua partecipazione al 30° Symposium Internazionale sulla Fibrillazione Atriale, che si terrà dal 16 al 18 gennaio 2025 a Boston, Massachusetts. L'AF Symposium, istituito nel 1995 in risposta all'epidemia crescente di fibrillazione atriale, si è evoluto in un significativo forum scientifico dove i professionisti della salute possono apprendere le ultime ricerche e i progressi terapeutici direttamente dai principali ricercatori.
Il CEO David Jenkins ha sottolineato che questi incontri offrono preziose opportunità per mettere in mostra le loro tecnologie, generare contatti di vendita e facilitare discussioni educative tra i medici sui loro prodotti, studi e tecniche cliniche.
Catheter Precision (NYSE American:VTAK) ha anunciado su participación en el 30° Simposio Internacional de Fibrilación Auricular, programado para el 16 al 18 de enero de 2025 en Boston, Massachusetts. El Simposio AF, establecido en 1995 en respuesta a la creciente epidemia de fibrilación auricular, ha evolucionado hasta convertirse en un foro científico significativo donde los profesionales de la salud pueden aprender sobre las últimas investigaciones y avances terapéuticos directamente de los principales investigadores.
El CEO David Jenkins enfatizó que estas reuniones proporcionan oportunidades valiosas para mostrar sus tecnologías, generar contactos de ventas y facilitar discusiones educativas entre médicos sobre sus productos, estudios y técnicas clínicas.
Catheter Precision (NYSE American:VTAK)는 2025년 1월 16일부터 18일까지 매사추세츠주 보스턴에서 열리는 제30회 국제 심방세동 심포지엄에 참여할 것이라고 발표했습니다. 1995년에 심방세동 유행에 대응하여 설립된 AF 심포지엄은 주요 연구자들로부터 최신 연구 및 치료 발전에 대해 직접 배울 수 있는 중요한 과학 포럼으로 발전했습니다.
CEO David Jenkins는 이러한 회의가 기술을 선보이고, 판매 기회를 창출하며, 의료진 간에 제품, 연구 및 임상 기술에 대한 교육적인 토론을 촉진할 수 있는 귀중한 기회를 제공한다고 강조했습니다.
Catheter Precision (NYSE American:VTAK) a annoncé sa participation au 30ème Symposium International sur la Fibrillation Auriculaire, qui se tiendra du 16 au 18 janvier 2025 à Boston, Massachusetts. Le Symposium AF, établi en 1995 en réponse à la multiplication des cas de fibrillation auriculaire, est devenu un forum scientifique majeur où les professionnels de la santé peuvent apprendre les dernières recherches et avancées thérapeutiques directement auprès des chercheurs de premier plan.
Le PDG David Jenkins a souligné que ces réunions offrent des opportunités précieuses pour présenter leurs technologies, générer des pistes commerciales et faciliter des discussions éducatives entre médecins sur leurs produits, études et techniques cliniques.
Catheter Precision (NYSE American:VTAK) hat seine Teilnahme am 30. Internationalen Symposium über Vorhofflimmern, das vom 16. bis 18. Januar 2025 in Boston, Massachusetts, stattfindet, bekannt gegeben. Das AF-Symposium, das 1995 als Reaktion auf die wachsende Epidemie des Vorhofflimmerns gegründet wurde, hat sich zu einem bedeutenden wissenschaftlichen Forum entwickelt, in dem Fachleute im Gesundheitswesen die neuesten Forschungen und therapeutischen Fortschritte direkt von führenden Forschern erfahren können.
CEO David Jenkins betonte, dass diese Treffen wertvolle Möglichkeiten bieten, um ihre Technologien zu präsentieren, Verkaufschancen zu generieren und Bildungsdiskussionen zwischen Ärzten über ihre Produkte, Studien und klinischen Techniken zu fördern.
- None.
- None.
FORT MILL, SOUTH CAROLINA / ACCESS Newswire / January 16, 2025 / Catheter Precision, Inc. (NYSE American:VTAK), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced their attendance at the 30th International Atrial Fibrillation Symposium in from January 16 - 18, 2025 in Boston, Massachusetts.
The AF Symposium was initiated in 1995 in response to the growing epidemic of atrial fibrillation. Over the past 30 years, the meeting has become a major scientific forum at which health care professionals have a unique opportunity to learn about advances in research and therapeutics directly from many of the most eminent investigators in the field.
David Jenkins, CEO of Catheter Precision, said, "Meetings allow us the chance to meet with physicians in a dedicated, focused setting and showcase our technologies while generating new sales leads. It also allows us to facilitate educational opportunities and physician-to-physician meetings to discuss our products, current and upcoming studies and best techniques for clinical success."
About Catheter Precision
Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to substantial risk and uncertainties. Forward-looking statements can be identified by words such as "believe," "anticipate," "may," "might," "can," "could," "continue," "depends," "expect," "expand," "forecast," "intend," "predict," "plan," "rely," "should," "will," "may," "seek," or the negative of these terms and other similar expressions, although not all forward-looking statements contain these words. These forward-looking statements include, but are not limited to, statements regarding product evaluations at the hospital, and that the purchase order indicates that the hospital and its staff see the value and benefits that LockeT can bring and expectations regarding LockeT evaluations in the coming weeks. The Company's expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks and changes in circumstances, including but not limited to risks and uncertainties included under the caption "Risk Factors" in the Company's Form 10-K filed with the SEC and available at www.sec.gov.
The forward-looking statements included in this communication are made only as of the date hereof. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
CONTACTS:
At the Company
David Jenkins
973-691-2000
info@catheterprecision.com
# # #
Contact Information
Missiaen Huck
COO
mhuck@catheterprecision.com
9736912000
SOURCE: Catheter Precision, Inc.
View the original press release on ACCESS Newswire
FAQ
When and where is Catheter Precision (VTAK) attending the 30th AF Symposium?
What is the significance of the AF Symposium where VTAK is presenting?
What are VTAK's objectives for attending the 2025 AF Symposium?
How long has the AF Symposium been running where VTAK is presenting?
